Oxford COVID Vaccine Safe, Effective, Especially in Older Adults

Grant Boone
November 22, 2020

"Our findings show that CoronaVac is capable of inducing a quick antibody response within four weeks of immunisation by giving two doses of the vaccine at a 14-day interval", said Professor Zhu Fengcai, one of the authors of the paper. These results are also consistent with the Phase I data that showed immunity in the adults from ages 18 to 55.

The early trials tested whether the vaccine produced an immune response, and also monitored side effects, using two different dosages and vaccine schedules. "The next step will be to see if this translates into protection from the disease itself", he added.

"Older adults are a priority group for COVID-19 vaccination, because they are at increased risk of severe disease, but we know that they tend to have poorer vaccine responses", Dr Maheshi Ramasamy, Investigator at the Oxford Vaccine Group and Consultant Physician, explained. The human body can become immune to the adenoviral vectors used in the vaccine, which makes booster shots more hard.

"The populations at greatest risk of serious Covid-19 disease include people with existing health conditions and older adults. We hope that this means our vaccine will help to protect some of the most vulnerable people in society, but further research will be needed before we can be sure", she said in the release.

All 560 participants in the study were healthy adults, with adverse reactions being less common in older adults than in younger ones. Moderna's vaccine is expected to be stable at normal fridge temperatures for 30 days but for storage of up to six months, it needs to be kept at minus 20 deg C.

Coronavirus: Christmas socialising poses 'substantial risks' - scientist
Speaking to BBC TV, Welsh First Minister Mark Drakeford said there would the details would be worked out at a meeting next week. Sage said the reproduction number - or R value - for the whole of the United Kingdom had dropped to between 1 and 1.1.

According to details, the vaccine that is undergoing the third phase of a clinical trial in Pakistan has shown positive results with 95 percent recovery rate of the patients who were about to be shifted on a ventilator. If other vaccines are also authorised, hundreds of millions of doses could be available by the spring, according to federal officials.

AstraZeneca and Oxford's vaccine works differently than the one created by Pfizer and Moderna.

The concerned institution that is supervising the entire clinical trial process of the vaccine is likely to announce its preparation during the ongoing month after the successful trial.

Separately, Pfizer's chief executive Albert Bourla said on Tuesday that the firm plans to submit its vaccine data to the US Food and Drug Administration for emergency-use authorisation.

Other reports by

Discuss This Article